Odyssey Therapeutics

“Odyssey’s accomplished team of scientists and executives with numerous prior successes in discovery, development and commercialization has made tremendous progress in only two years. Dr. Glick has successfully created a sustainable and capital-efficient model that primes Odyssey to be a hub for immunology and oncology therapeutic innovation, and I look forward to working with him, the board and leaders on the management team in the years ahead.” Dr. Lorence Kim, co-founder and managing partner of Ascenta Capital Today, we announce the closing of a $101 million Series C financing round led by Ascenta Capital with participation from new and existing investors, and welcome Dr. Lorence Kim to our board of directors. This funding will support the advancement of multiple programs into clinical studies and the continuation of investment in discovery to build a sustainable model for therapeutic innovation. Read the full press release: https://lnkd.in/gHVi7K2q #Biotech #DrugDiscovery #PrecisionMedicine #Therapeutics

Meet #EmployeeSpotlight Dominik Kölmel, Director of Chemistry at #TeamOdyssey. Approaching his three-year work anniversary, Dominik was drawn to Odyssey’s commitment to bringing next-generation precision medicines to patients in need. 🔬 His proudest achievement so far at Odyssey is helping to advance our lead program to clinic. 🌍 Outside of work, Dominik enjoys traveling, and his favorite experience was a memorable trip to Hawaii. 🍽️ If he could host a dinner party with any three people, Dominik would invite Albert Einstein, Mark Hamill, and Steven Erikson.

Come join our team!

Our next #EmployeeSpotlight is Ryan F., Machine Learning Research Scientist. He joined #TeamOdyssey full-time after participating in the Company’s 2023 internship program to pursue his passion for #MachineLearning and its interdisciplinary applications. He enjoys his role because it exposes him to innovative industry research practices, challenging implementation and engineering problems, and new types of science. Outside of work, Ryan is an avid runner and loves studying languages. 🌍🏃♂️

“With the addition of Dr. Roush to our team of drug hunters, I am confident Odyssey will continue to develop the best therapeutic candidates to potentially change the standard of care for patients living with serious immune diseases,” said Gary D. Glick, founder and CEO of Odyssey Therapeutics. Odyssey is pleased to introduce William Roush, Ph.D., as executive vice president and head of small molecule research. Dr. Roush will leverage his experience and expertise to oversee the prosecution of Odyssey’s small molecule, preclinical portfolio from target selection into early development. Read more of William's impressive resume in our press release: https://lnkd.in/gd-gkfqF #Leadership #Biotech #DrugDiscovery #PrecisionMedicine #Therapeutics

Meet today’s #EmployeeSpotlight, Maria (Dai) Tianero-McIntosh, Associate Director of Natural Products Enabling Sciences at #TeamOdyssey. Dai joined Odyssey nearly three years ago to immerse herself in drug discovery and development, learning from industry leaders and colleagues with a proven track record. She is particularly excited about reintegrating Natural Products into discovery pipelines. Dai's favorite aspect of her job is working alongside colleagues who come from various backgrounds and possess a wide range of expertise. Outside of work, Dai loves exploring new places around Boston and New England with her husband and their two young children. They enjoy visiting beaches 🏖️, gardens 🌺, and engaging in various family-friendly activities.

Our next #EmployeeSpotlight features Jim Ferrucci, Corporate Controller. Jim joined #TeamOdyssey last year, working with colleagues across all functions to learn about the fascinating science behind drug discovery and development. He believes in our success because everyone is driven, passionate about making a difference, and committed to our mission. Outside of work, Jim enjoys spending time with his wife and two daughters, playing in a hockey league, saltwater fishing, and golfing.

Meet today’s #EmployeeSpotlight Laura Preiss, Director of Protein Therapeutics. Laura joined #TeamOdyssey 2.5 years ago, drawn by the excellent science and outstanding team members. Each and every morning, it's the stimulating and inspiring scientific discussions that draw Laura to Odyssey. Outside of work, Laura enjoys memorable experiences like road trips through Florida, finds inspiration in Yotam Ottolenghi's cookbooks, and indulges in caring for her orchids. We’re happy to have her here at Odyssey!

Yesterday, Odyssey's Chief Data Officer Joseph Mcdonald joined industry leaders from Johnson & Johnson Innovative Medicine, BigHat Biosciences, Sequome, and Samsara BioCapital for a panel discussion on the opportunities and challenges of using #AI and #ML tools for hit identification, multiparameter optimization, and in vivo property prediction to accelerate #DrugDiscovery in small molecules. During the session they were asked for their opinions on the impact of AI/ML in the industry over the next three to five years. Joe shared: “It could be that we will see new ways of monitoring patients, where instead of just using the maximum tolerated dose, we use machine learning to monitor patients more effectively. This allows us to titrate their dose, so treatments are effective and avoid toxicology risks.” Thank you, Biotechnology Innovation Organization, for hosting us and orchestrating an amazing event! #BIO2024

“What we want ultimately are scientists to leverage machine learning to see and observe trends, while using their own scientific knowledge as a filter, and be better as a result of seeing those ideas from machine learning.” Today Joseph Mcdonald, Odyssey's Chief Data Officer, participated in a #BIO2024 panel discussion titled “AI and Machine Learning Transforming R&D and Business.” Joe highlighted the power of #AI and #ML in drug discovery and emphasized the crucial role of scientists in interpreting and utilizing these insights. He shared how Odyssey has a multi-disciplinary team of scientists who understand drug discovery and can effectively integrate machine learning into decision-making processes. Joe will participate in another panel tomorrow from 11:00 a.m. to 12:00 p.m. PT in section 30ABC for a session titled “Using AI/ML for Identification and Optimization of Therapeutic Molecules.” We encourage those attending #BIO2024 to stop by and listen in.